LEO Pharma A/S, a global leader in medical dermatology, today announced the positive results from a 16-week interim analysis of the Phase 3b ADHAND trial evaluating tralokinumab for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback